Immunosuppressives and biologics during pregnancy and lactation

• DOI: 10.1007/s00508-019-1448-y
• Publication Date: 2019-01-14T05:38:27Z
• Authors: Antonia Puchner; Hans Peter Gröchenig; Judith Sautner; Yvonne Helmy-Bader; Herbert Juch; Sieglinde Reinisch; Christoph Högenauer; Robert Koch; Josef Hermann; Andrea Studnicka-...; Wolfgang Weger; Rudolf Puchner; Clemens Dejaco
• Keywords: Biological Products; Consensus; Gastroenterology; Infant, Newborn; Consensus Report; Inflammatory Bowel Diseases; 3. Good health; Pregnancy Complications; 03 medical and health sciences; 0302 clinical medicine; Rheumatology; Pregnancy; Austria; Humans; Immunologic Factors; Lactation; Female

An increasing and early-onset use of immunosuppressives biologics has become more frequently seen among patients with inflammatory bowel diseases (IBD) rheumatic disorders. Many women in their childbearing years currently receive such medications, some them an interdisciplinary setting. questions arise already pregnant or wishing to conceive respect continuing discontinuing treatment, the risks borne by newborns mothers long-term safety. Together Austrian Society Rheumatology Rehabilitation, IBD working group Gastroenterology Hepatology elaborated consensus statements on pregnancy lactation. This is first this topic. It intended serve as a basis support for providing advice our treating physicians.